Fig. 2
From: Saliva-based lacosamide monitoring paves the way toward personalized epilepsy pharmacotherapy
Development of the population PK model for lacosamide. (A) Structure of lacosamide PK model, including a scale factor for plasma-to-saliva distribution of lacosamide. Ka, first order rate constant; CL/F, apparent clearance. (B) Goodness-of-fit-plots for the PK model of lacosamide, comparing observations with population and individual predictions, and displaying CWRES versus population predictions and time after last dose. (C) A prediction corrected visual predictive check of lacosamide model, stratified by blood and saliva groups. This part includes 500 simulated datasets. The observed concentrations are indicated by closed circles, with solid lines representing the 5th (blue), median (red), and 95th (blue) percentiles of the observed concentrations. The shaded blue and red areas highlight the 95% confidence intervals of the simulated concentrations for each percentile. CWRES conditional weighted residuals; PK pharmacokinetics.
